Haopeng Rui

Haopeng Rui serves as the Executive Director at D3 Bio, leading Translational Research and Biologics Discovery since March 2021. Prior experience includes a role as Senior Director at Johnson & Johnson from March 2017 to March 2021, where responsibility included overseeing Oncology Translational Research and focusing on clinical biomarker development and understanding disease mechanisms. Earlier roles include Associate Director and Director at Reyoung Pharmaceutical Co., Ltd. from March 2012 to March 2017, managing targeted therapy projects and biological lab teams, and a position as Scientist at Pfizer from August 2010 to March 2012, leading drug discovery projects and a research team. Haopeng Rui holds a Ph.D. in Microbiology and Immunology from Harvard Medical School and a Ph.D. in Biochemical Engineering from East China University of Science and Technology.